The IDO1 Knockout MCF-7 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population with targeted disruption of the IDO1 gene in the MCF-7 human breast adenocarcinoma cell line. This heterogeneous pool enables loss-of-function studies without clonal selection artifacts, suitable for assays where population-level effects are desired.
MCF-7 is an estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and human epidermal growth factor receptor 2 (HER2)-negative luminal A breast cancer model widely used in hormone-responsive tumor research. Its epithelial origin and well-characterized signaling provide a relevant background for investigating IDO1-mediated immunometabolic pathways.
IDO1 initiates tryptophan degradation via the kynurenine pathway, producing N-formylkynurenine, which leads to tryptophan depletion and kynurenine accumulation. Kynurenine acts as an endogenous ligand for the aryl hydrocarbon receptor (AhR), promoting FOXP3-dependent regulatory T cell differentiation and suppressing effector T-cell responses. Upstream regulators include interferon-gamma (IFNG), tumor necrosis factor (TNF), interleukin-6 (IL-6), and prostaglandin E2 (PGE2); downstream targets involve AhR, mTOR, and GCN2 kinase. Heme cofactor, cytochrome b5, and SOCS3 interact with IDO1 to modulate its activity.
In the MCF-7 context, IDO1 may contribute to immune evasion by generating kynurenine and activating AhR. Disruption of IDO1 allows examination of how loss of tryptophan catabolism alters immunomodulatory metabolite production and AhR-driven signaling, potentially restoring antitumor immunity in a hormone-responsive breast cancer background.
Primary research applications include immune checkpoint blockade studies, tumor microenvironment manipulation, and metabolic immunotherapy development. Representative assays involve co-culture with peripheral blood mononuclear cells (PBMCs) to assess T-cell proliferation, activation markers (CD69, CD25), and cytokine secretion (IL-2, IFN-gamma) via flow cytometry or ELISA. Kynurenine quantification by LC-MS, AhR reporter assays, Western blotting, and RT-qPCR enable pathway analysis. For additional details, contact Ascent Research.
